Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies
- PMID: 35765315
- PMCID: PMC9129196
- DOI: 10.1093/ofid/ofac171
Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies
Abstract
Background: Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies.
Methods: In the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation's largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including healthcare workers and first responders).
Results: Several studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes.
Conclusions: In this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.
Keywords: COVID-19; SARS-CoV-2; SeroNet; cohort; epidemiology; serosurveillance.
© The Author(s) 2022.. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
Similar articles
-
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.mSphere. 2022 Aug 31;7(4):e0019322. doi: 10.1128/msphere.00193-22. Epub 2022 Jun 15. mSphere. 2022. PMID: 35703544 Free PMC article.
-
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.medRxiv [Preprint]. 2022 Mar 14:2022.02.27.22271399. doi: 10.1101/2022.02.27.22271399. medRxiv. 2022. Update in: mSphere. 2022 Aug 31;7(4):e0019322. doi: 10.1128/msphere.00193-22. PMID: 35262095 Free PMC article. Updated. Preprint.
-
The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop.Hum Vaccin Immunother. 2023 Aug 1;19(2):2253598. doi: 10.1080/21645515.2023.2253598. Hum Vaccin Immunother. 2023. PMID: 37695268 Free PMC article.
-
Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes.Can Respir J. 2020 Sep 5;2020:1401053. doi: 10.1155/2020/1401053. eCollection 2020. Can Respir J. 2020. PMID: 32934758 Free PMC article. Review.
-
A compendium answering 150 questions on COVID-19 and SARS-CoV-2.Allergy. 2020 Oct;75(10):2503-2541. doi: 10.1111/all.14449. Epub 2020 Jul 20. Allergy. 2020. PMID: 32535955 Free PMC article. Review.
Cited by
-
Targeted electronic health record-based recruitment strategy to enhance COVID-19 vaccine response clinical research study enrollment.Contemp Clin Trials Commun. 2023 Dec 20;37:101250. doi: 10.1016/j.conctc.2023.101250. eCollection 2024 Feb. Contemp Clin Trials Commun. 2023. PMID: 38312474 Free PMC article.
-
3D hydrogel/ bioactive glass scaffolds in bone tissue engineering: Status and future opportunities.Heliyon. 2023 Jul 5;9(7):e17050. doi: 10.1016/j.heliyon.2023.e17050. eCollection 2023 Jul. Heliyon. 2023. PMID: 37483767 Free PMC article. Review.
-
The 2022 Report on the Human Proteome from the HUPO Human Proteome Project.J Proteome Res. 2023 Apr 7;22(4):1024-1042. doi: 10.1021/acs.jproteome.2c00498. Epub 2022 Nov 1. J Proteome Res. 2023. PMID: 36318223 Free PMC article. Review.
-
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.mSphere. 2022 Aug 31;7(4):e0019322. doi: 10.1128/msphere.00193-22. Epub 2022 Jun 15. mSphere. 2022. PMID: 35703544 Free PMC article.
References
-
- Lurie N, Saville M, Hatchett R, Halton J.. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020; 382:1969–73. - PubMed
-
- National Cancer Institute. Serological Sciences network to study COVID Immune response. Available at: https://www.cancer.gov/research/key-initiatives/covid-19/coronavirus-res.... Accessed 2021.
Grants and funding
- U01 CA260513/CA/NCI NIH HHS/United States
- U01 CA260539/CA/NCI NIH HHS/United States
- U01 CA261276/CA/NCI NIH HHS/United States
- U01 CA260469/CA/NCI NIH HHS/United States
- K01 MD015079/MD/NIMHD NIH HHS/United States
- U01 CA260462/CA/NCI NIH HHS/United States
- U54 CA260543/CA/NCI NIH HHS/United States
- U01 CA260507/CA/NCI NIH HHS/United States
- U01 CA260526/CA/NCI NIH HHS/United States
- U01 CA261277/CA/NCI NIH HHS/United States
- U54 CA260560/CA/NCI NIH HHS/United States
- U54 CA260591/CA/NCI NIH HHS/United States
- U01 CA260584/CA/NCI NIH HHS/United States
- U01 CA260541/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous